Inside informationFrench
Ipsen fait le point sur l'essai de Phase II FALKON chez les patients atteints d’une maladie osseuse ultra-rare, la fibrodysplasie ossifiante progressive (FOP)
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Ipsen SA
- Filed
- 19/12/2025, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- French
- AMF reference
- 135778_20251219